A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of HJB647 in Participants With Chronic Stable Heart Failure With Reduced Ejection Fraction
Latest Information Update: 21 Apr 2026
At a glance
- Drugs HJB 647 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Novartis
Most Recent Events
- 15 Apr 2026 Planned End Date changed from 21 Sep 2026 to 24 Sep 2026.
- 15 Apr 2026 Planned primary completion date changed from 21 Sep 2026 to 24 Sep 2026.
- 15 Apr 2026 Status changed from not yet recruiting to recruiting.